Brief: Transcode Therapeutics Reports Prelim Results of Phase 0 Clinical Study With Lead Candidate

Transcode Therapeutics

24/10/2023 14:00

Oct 24 (Reuters) - Transcode Therapeutics Inc  RNAZ.O :
    * TRANSCODE THERAPEUTICS - ANNOUNCES PRELIMINARY CLINICAL
RESULTS
IN FIRST PATIENT IN PHASE 0 CLINICAL STUDY WITH LEAD THERAPEUTIC
CANDIDATE, TTX-MC138
    * TRANSCODE THERAPEUTICS - RADIOLABELED TTX-MC138 HAD
PHARMACOKINETIC BEHAVIOR CONSISTENT WITH THAT EXPECTED BASED ON
NON-CLINICAL IND-ENABLING STUDIES
    * TRANSCODE THERAPEUTICS INC - PATIENT TOLERATED DOSING WITH
NO
REPORTED ADVERSE REACTIONS
    * TRANSCODE THERAPEUTICS - COMPLETE ANALYSIS OF DATA FROM
FIRST
PATIENT IS IN PROCESS, TO BE INCLUDED IN FINAL REPORT FOR ALL
PATIENTS ENROLLED IN STUDY

Source text for Eikon:  ID:nGNX4Q0dcp 
Further company coverage:  RNAZ.O 

 ((Reuters.Briefs@thomsonreuters.com))